瑞思迈 2026年季度报告

FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December31, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ ResMed Inc. (Exact name of registrant as specified in its charter)______________________________________________________________________________________________ Delaware(State or other jurisdiction of incorporation or organization)98-0152841(I.R.S. Employer Identification No.)9001 Spectrum Center Blvd.San Diego, CA 92123United States of America(Address of principal executive offices, including zip code)(858) 836-5000(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated FilerNon-Accelerated FilerEmerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo At January26, 2026 there were 145,678,401 shares of Common Stock ($0.004 par value) outstanding. This number excludes45,152,661 shares held by the registrant as treasury shares. INDEX Part IFinancial Information3Item 1Financial Statements3Condensed Consolidated Balance Sheets (Unaudited)3Condensed Consolidated Statements of Operations (Unaudited)4Condensed Consolidated Statements of Comprehensive Income (Unaudited)5Condensed Consolidated Statements of Changes in Equity (Unaudited)6Condensed Consolidated Statements of Cash Flows (Unaudited)8Notes to the Condensed Consolidated Financial Statements (Unaudited)9Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item 3Quantitative and Qualitative Disclosures About Market Risk37Item 4Controls and Procedures40Part IIOther Information41Item 1Legal Proceedings41Item 1ARisk Factors41Item 2Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities41Item 3Defaults Upon Senior Securities41Item 4Mine Safety Disclosures41Item 5Other Information41Item 6Exhibits43Signatures44 RESMED INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited) (In US$ and in thousands, except share and per share data) RESMED INC. AND SUBSIDIARIESCondensed Consolidated Statements of Operations (Unaudited)(In US$ and in thousands, except per share data) RESMED INC. AND SUBSIDIARIESCondensed Consolidated Statements of Comprehensive Income (Unaudited)(In US$ and in thousands) RESMED INC. AND SUBSIDIARIESCondensed Consolidated Statements of Changes in Equity (Unaudited)(In US$ and in thousands) RESMED INC. AND SUBSIDIARIESCondensed Consolidated Statements of Changes in Equity (Unaudited) (In US$ and in thousands) RESMED INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows (Unaudited)(In US$ and in thousands) Six Months EndedDecember 31, RESMED INC. AND SUBSIDIARIESNotes to the Condensed Consolidated Financial Statements(Unaudited) (1)Summary of Significant Accounting Policies Organization and Basis of Presentation ResMed Inc., or Resmed, we, us, our or the Company, is a Delaware corporation formed in March 1994 as a holding company for theResmed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located inAustralia, Singapore, Malaysia, France, China and the United States, or the U.S. Major distribution and sales sites are located in theU.S., Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and